619 results on '"van der Woude, C. Janneke"'
Search Results
2. Patients with immune mediated inflammatory diseases are insufficiently protected against vaccine-preventable infections
3. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
4. Evaluation of walking activity and gait to identify physical and mental fatigue in neurodegenerative and immune disorders: preliminary insights from the IDEA-FAST feasibility study
5. Dutch normative data of the sexual distress scale and the body image scale
6. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease
7. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
8. Endoscopic management of patients with high-risk colorectal colitis–associated neoplasia: a Delphi study
9. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
10. Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease
11. Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study
12. Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies
13. Systematic review: Patient‐related, microbial, surgical, and histopathological risk factors for endoscopic post‐operative recurrence in patients with Crohn's disease.
14. Addition of Platelet-Rich Plasma to Endorectal Advancement Flap Repair Does Not Enhance the Healing of Cryptoglandular Transsphincteric Fistulas.
15. Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn’s disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy
16. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study
17. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease
18. Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn’s disease
19. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease
20. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
21. S6 Pregnancy Outcomes in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis: Results From the Ozanimod Clinical Development Program
22. A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process
23. Validation of the pharmacokinetic model for anti- TNFα clearance in infants exposed to anti- TNFα during pregnancy
24. Health-related quality of life in the first 5 years of the children born to mothers with IBD does not differ from children born to healthy mothers
25. Rotterdam Transition Test: A Valid Tool for Monitoring Disease Knowledge in Adolescents With Inflammatory Bowel Disease
26. Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn's Disease.
27. Impact of timing of primary ileocecal resection on prognosis in patients with Crohn’s disease
28. Identification of Fatigue and Sleepiness in Immune and Neurodegenerative Disorders from Measures of Real-World Gait Variability
29. Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies
30. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management
31. TNF-α exerts potent anti-rotavirus effects via the activation of classical NF-κB pathway
32. Cholecystectomy Risk in Crohn’s Disease Patients After Ileal Resection: a Long-term Nationwide Cohort Study
33. Fatigue in IBD: epidemiology, pathophysiology and management
34. Promoting equity in inflammatory bowel disease: a global approach to care
35. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.
36. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
37. Cardiovascular risk profiles in patients with inflammatory bowel disease differ from matched controls from the general population
38. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study
39. Autologous Platelet-Rich Stroma in Complex Perianal Fistulas
40. Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial
41. Isolated ileal blind loop inflammation after intestinal resection with ileocolonic anastomosis in Crohn’s disease: an often neglected endoscopic finding with an unfavorable outcome
42. Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry
43. 115 - ACONTECIMIENTOS ADVERSOS TROMBOEMBÓLICOS, CARDIOVASCULARES MAYORES ENTRE LOS PACIENTES INCLUIDOS EN EL PROGRAMA DE ENSAYOS CLÍNICOS DE FILGOTINIB
44. SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis
45. Preconception Care Reduces Relapse of Inflammatory Bowel Disease During Pregnancy
46. sj-docx-1-tag-10.1177_17562848231174295 – Supplemental material for SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis
47. Fecal Matrix Metalloproteinase-9 Measurement for Optimizing Detection of Disease Activity in Inflammatory Bowel Disease
48. Comment on “Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease”
49. Modulatory Effects of Pregnancy on Inflammatory Bowel Disease
50. Incidence of Interval Colorectal Cancer Among Inflammatory Bowel Disease Patients Undergoing Regular Colonoscopic Surveillance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.